Transporters as a determinant of drug clearance and tissue distribution

被引:376
作者
Shitara, Y
Horie, T
Sugiyama, Y
机构
[1] Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Mol Pharmacokinet, Bunkyo Ku, Tokyo 1130033, Japan
[2] Chiba Univ, Grad Sch Pharmaceut Sci, Dept Biopharmaceut, Chuo Ku, Chiba 2608675, Japan
关键词
transporter; drug elimination; pharmacokinetics;
D O I
10.1016/j.ejps.2005.12.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Transporters play an important role in the processes of drug absorption, distribution and excretion. In this review, we have focused on the involvement of transporters in drug excretion in the liver and kidney. The rate of transporter-mediated uptake and efflux determines the rate of renal and hepatobiliary elimination. Transporters are thus important as a determinant of the clearance in the body Even when drugs ultimately undergo metabolism, their elimination rate is sometimes determined by the uptake rate mediated by transporters. Transporters regulate the pharmacological and/or toxicological effect of drugs because they limit their distribution to tissues responsible for their effect and/or toxicity. For example, the liver-specific distribution of some statins via organic anion transporters helps them to produce their high pharmacological effect. on the other hand, as in the case of metformin taken up by organic cation transporter 1, drug distribution to the tissue(s) may enhance its toxicity. As transporter-mediated uptake is a determinant of the drug elimination rate, drug-drug interactions involving the process of transporter-mediated uptake can occur. In this review, we have introduced some examples and described their mechanisms. More recently, some methods to analyze such transporter-mediated transport have been reported. The estimation of the contributions of transporters to the net clearance of a drug makes it possible to predict the net clearance from data involving drug transport in transporter-expressing cells. Double transfected cells, where both uptake and efflux transporters are expressed on the same polarized cells, are also helpful for the analysis of the rate of transporter-mediated transcellular transport. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:425 / 446
页数:22
相关论文
共 151 条
[1]  
Abu-Zahra TN, 2000, DRUG METAB DISPOS, V28, P801
[2]  
AMIDON GL, 1994, ANNU REV PHARMACOL, V34, P321
[3]   A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers [J].
Amsden, GW ;
Kuye, O ;
Wei, GCG .
JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (04) :444-449
[4]   Gemfibrozil greatly increases plasma concentrations of cerivastatin [J].
Backman, JT ;
Kyrklund, C ;
Neuvonen, M ;
Neuvonen, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (06) :685-691
[5]   CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide [J].
Bidstrup, TB ;
Bjornsdottir, I ;
Sidelmann, UG ;
Thomsen, MS ;
Hansen, KT .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (03) :305-314
[6]   Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A [J].
Binet, I ;
Wallnöfer, A ;
Weber, C ;
Jones, R ;
Thiel, G .
KIDNEY INTERNATIONAL, 2000, 57 (01) :224-231
[7]   Transport of cimetidine by flounder and human renal organic anion transporter 1 [J].
Burckhardt, BC ;
Brai, S ;
Wallis, S ;
Krick, W ;
Wolff, NA ;
Burckhardt, G .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2003, 284 (03) :F503-F509
[8]   Identification of organic anion transporting polypeptide 4 (Oatp4) as a major full-length isoform of the liver-specific transporter-1 (rlst-1) in rat liver [J].
Cattori, V ;
Hagenbuch, B ;
Hagenbuch, N ;
Stieger, B ;
Ha, R ;
Winterhalter, KE ;
Meier, PJ .
FEBS LETTERS, 2000, 474 (2-3) :242-245
[9]   Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney [J].
Cha, SH ;
Sekine, T ;
Fukushima, J ;
Kanai, Y ;
Kobayashi, Y ;
Goya, T ;
Endou, H .
MOLECULAR PHARMACOLOGY, 2001, 59 (05) :1277-1286
[10]   Effect of OATPIBI (SLCOIBI) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers [J].
Chung, JY ;
Cho, JY ;
Yu, KS ;
Kim, JR ;
Oh, DS ;
Jung, HR ;
Lim, KS ;
Moon, KH ;
Shin, SG ;
Jang, IJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (04) :342-350